The InRhythm™ Program – Inhaled Antiarrhythmic for PAF

A breath of fresh air for
Paroxysmal Atrial Fibrillation patients.

Introducing the InRhythm™ Therapy

A Patient-Administered, Inhaled Antiarrhythmic for Acute Treatment of Paroxysmal Atrial Fibrillation (PAF)

InRhythm is a novel inhaled therapeutic candidate designed to rapidly deliver flecainide, a well-established antiarrhythmic agent, to the heart via the lungs, converting patients back to a normal sinus rhythm (NSR) and relieving symptoms following the onset of a PAF episode.

The therapy is being developed as a portable treatment that can be self-administered by patients in any setting to rapidly trigger NSR conversion, as well as for use under medical supervision in a hospital, emergency room or physician office.

  • Advantages of Inhaled Therapy for AF

  • 1. Patient self-administered, allowing for fast, convenient treatment anywhere
    2. Therapy can be initiated earlier, at the first signs of an episode, thus reducing disabling symptoms and/or possibly avoiding ER visits and hospitalizations
    3. Rapidly absorbed through the lung and delivered to the heart
    4. Rapid onset and conversion to normal sinus rhythm
    5. Low drug dose and short duration of action, to minimize potential side effects

Actual AFib Patients React to InRhythm™

Actual Atrial Fibrillation (AFib) patients provide feedback on the InRhythm™ product concept.

For more information about InCarda: